R&G PharmaStudies Co., Ltd. (SHE:301333)
China
· Delayed Price · Currency is CNY 63.47
-2.36 (-3.58%)
At close: Apr 29, 2026
R&G PharmaStudies Revenue
R&G PharmaStudies had revenue of 218.09M CNY in the quarter ending March 31, 2026, with 26.18% growth. This brings the company's revenue in the last twelve months to 896.26M, up 21.20% year-over-year. In the year 2025, R&G PharmaStudies had annual revenue of 851.01M with 14.38% growth.
Revenue (ttm)
896.26M
Revenue Growth
+21.20%
P/S Ratio
6.80
Revenue / Employee
338.85K
Employees
2,645
Market Cap
6.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 851.01M | 107.00M | 14.38% |
| Dec 31, 2024 | 744.00M | 22.63M | 3.14% |
| Dec 31, 2023 | 721.37M | 83.85M | 13.15% |
| Jan 1, 2023 | 637.52M | 29.09M | 4.78% |
| Jan 1, 2022 | 608.43M | 123.98M | 25.59% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2013 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xiangxue Pharmaceutical | 1.47B |
| Innovita Biological Technology | 422.03M |
| Shouyao Holdings (Beijing) Co., LTD. | 34.67M |
| Lifecome Biochemistry | 502.95M |
| Wuhan Keqian Biology Co.,Ltd | 949.74M |
| PharmaResources (Shanghai) | 667.47M |
| Novogene | 2.26B |
| Shenzhen Weiguang Biological Products | 1.26B |